Chemosensitivity test using subrenal capsule assays

Part 2. Clinical evaluation in fresh human lung cancer

Abstract

Clinical evaluation of a new chemosensitivity test using a subrenal capsule assay was performed. Chemosensitivity testing by SRC was performed on 28 fresh human lung cancer tissue samples. Eight of 10 cases were evaluable in squamous cell carcinoma, 3 of 11 in adenocarcinoma, 3 of 5 in small cell carcinoma, and 0 of 2 in other lung cancers. The factors affecting the evaluable assay rate were the abundance of cancer cells in tumor specimens and the tumor histological type. More cases of squamous cell carcinoma and small cell carcinoma were evaluable than of adenocarcinoma. In evaluable cases, tumor volume regression over 50% was seen in 4 of 14 assays using CDDP, 3 of 12 with CPA, and 6 of 11 with ADM. Regression over 70% was seen in 3 of 14 with CDDP, 1 of 12 with CPA, and 1 of 11 with ADM. In the drug-treated groups, tumor regression rates and histological effects were only weakly correlated.